SMC expands guidance for Lokelma to emergency care settings
New access to treatment involves adult patients with hyperkalaemia across Scotland
Read More
Tag: Lokelma
SMC accepts 14 new medicines for use by NHS Scotland
The decisions bring a raft of new treatment options for conditions including epilepsy, depression and cancer
Read More
EU approves label update for AZ’ Lokelma
Update provides dosing regimen specifically for hyperkalaemia in patients with end-stage renal disease on stable haemodialysis
Read More
US clears label update for AZ’ Lokelma
The drug’s label now includes a dosing regimen specifically to treat hyperkalaemia in patients with end-stage renal disease on stable hemodialysis
Read More
NICE expands draft recommendation for Lokelma
The news comes shortly after AZ announced positive results from a late-stage trial of the drug.
Read More
NICE turns down hyperkalaemia therapies
Preliminary guidelines released by the National Institute for Health and Care Excellence do not recommend NHS funding for hyperkalaemia treatments Lokelma and Veltassa.
Read More
US green light for AZ’ Lokelma
US regulators have finally issued a green light for AstraZeneca’s Lokelma as a treatment for hyperkalaemia – elevated potassium levels in the blood – in adult patients.
Read More
EU approves AZ’ potassium binder for hyperkalaemia
AstraZeneca’s Lokelma has been approved in Europe to treat hyperkalaemia in adult patients.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
